临床研究

早期多原发与单发肺腺癌结节的临床特征及淋巴结转移风险对比

  • 杨家明 ,
  • 谢诗 ,
  • 周海深 ,
  • 张家庆
展开
  • 南方医科大学珠江医院胸外科 (广东 广州 510280 )

收稿日期: 2024-08-22

  网络出版日期: 2024-11-25

基金资助

广东省科技计划项目(2019A141405014)

A comparative study of clinical features and lymph node metastasis risk between early multi⁃primary and singlee pulmonary adenocarcinoma nodules

  • Jiaming YANG ,
  • Shi XIE ,
  • Haishen ZHOU ,
  • Jiaqing ZHANG
Expand
  • Department of Thoracic surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,Guangdong,China

Received date: 2024-08-22

  Online published: 2024-11-25

摘要

目的 探讨多原发肺腺癌结节与单发肺腺癌结节的临床特征和淋巴结转移风险差异。 方法 回顾分析南方医科大学珠江医院胸外科于2022~2023年收治的手术患者212例,其中单发肺腺癌结节(149例)和多原发肺腺癌结节(63例),经倾向性评分匹配后比较两组影像学特征、肿瘤血清学指标、病理免疫组化及淋巴结转移率,运用二元logistic回归探讨单发与多发对其淋巴结转移率的差异。 结果 经过倾向性评分匹配,两组在CT的Avr值(P = 0.001)、KI-67表达水平(P < 0.001)、PD-L1表达水平(P = 0.002)及淋巴结转移率(P = 0.030)上差异有统计学意义,但在结节类型、影像学特征(分叶征、血管集束征等)、肿瘤血清学指标(CEA、NSE等)、ALK阳性率和SYN阳性率上差异均无统计学意义。筛选有显著差异的变量(Avr、Ki-67、PD-L1),经Spearman法检验发现存在相关性。以是否发生淋巴结转移为因变量,纳入单发或多发作为分类协变量、交互纳入以上3个相关性显著的变量为自变量进行二元logistic回归分析,发现多原发腺癌结节较单发腺癌结节发生淋巴结转移的概率低80.8%(RR = 0.192,P = 0.042)。 结论 多原发腺癌结节较单发腺癌结节生物学行为较温和,发生淋巴结转移的概率较低;对于多原发肺腺癌结节,应基于术中冰冻病理及影像学等综合评估,制定个性化的治疗方案。

本文引用格式

杨家明 , 谢诗 , 周海深 , 张家庆 . 早期多原发与单发肺腺癌结节的临床特征及淋巴结转移风险对比[J]. 实用医学杂志, 2024 , 40(22) : 3208 -3214 . DOI: 10.3969/j.issn.1006-5725.2024.22.015

Abstract

Objective To investigate the clinical characteristics and risk of lymph node metastasis in patients with multiple primary lung adenocarcinoma nodules compared to those with a single lung adenocarcinoma nodule. Methods Retrospective analysis was conducted on 212 patients who underwent thoracic surgery at Zhujiang Hospital of Southern Medical University from 2022 to 2023. This included 149 cases of single lung adenocarcinoma nodules and 63 cases of multiple primary lung adenocarcinoma nodules. After propensity score matching, a comparison was made between the two groups in terms of imaging features, tumor serological indicators, pathological immunohistochemistry, and lymph node metastasis rate. Additionally, binary logistic regression was employed to explore the differences in lymph node metastasis rate between single and multiple nodules. Results After propensity score matching, statistically significant differences were observed in the Avr value of CT (P = 0.001), KI?67 expression level (P < 0.001), PD?L1 expression level (P = 0.002), and lymph node metastasis rate (P = 0.030) between the two groups. However, there were no statistically significant differences in nodule type, imaging features such as lobulation and vascular clustering, tumor serological indicators including CEA and NSE, ALK positive rate, and SYN positive rate. The variables with significant differences (Avr, Ki?67, PD?L1) were identified through Spearman test for correlation analysis. Binary logistic regression analysis was performed using lymph node metastasis as the dependent variable and single or multiple nodules as categorical covariates along with the three correlated variables included as independent variables interactively. The results showed that the probability of lymph node metastasis in multiple primary lung adenocarcinoma nodules was 80.8% lower than that in single lung adenocarcinoma nodules (RR = 0.192, P = 0.042). Conclusions Multiple primary adenocarcinoma nodules exhibit a less aggressive biological behavior compared to solitary adenocarcinoma nodules, resulting in a reduced likelihood of lymph node metastasis. For cases involving multiple primary lung adenocarcinoma nodules, the implementation of aggressive surgical protocols is not advisable; instead, personalized treatment plans should be developed based on comprehensive evaluations including intraoperative frozen pathology and imaging.

参考文献

1 BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229?263. doi:10.3322/caac.21834
2 HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. Natl Cancer Cent, 2024, 4(1): 47?53. doi:10.1016/j.jncc.2024.01.006
3 LEITER A, VELUSWAMY R R, WISNIVESKY J P. The global burden of lung cancer: Current status and future trends[J]. Nat Rev Clin Oncol, 2023, 20(9): 624?639. doi:10.1038/s41571-023-00798-3
4 吴雪杰,陈东来,朱蓉英,等.多发肺结节的基础研究和临床治疗进展[J].中国肺癌杂志,2019,22(3):173-177.
5 钟华,姚烽,陈群慧,等.肺部多发结节的诊断和治疗[J]. 中华肿瘤杂志,2023,45(6):455-463.
6 ZHANG Y K, CHAI Z, TAN L, et al. Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer[J]. World J Surg Oncol, 2017, 15(1): 1?8. doi:10.1186/s12957-017-1098-3
7 NICHOLSON A G, TSAO M S, BEASLEY M B, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015[J]. Thorac Oncol Off Publ Int Assoc Study Lung Cancer,2022, 17(3): 362?387. doi:10.1016/j.jtho.2021.11.003
8 LORTET-TIEULENT J, SOERJOMATARAM I, FERLAY J, et al. International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women[J]. Lung Cancer Amst Neth, 2014, 84(1): 13?22. doi:10.1016/j.lungcan.2014.01.009
9 中华医学会呼吸病学分会间质性肺疾病学组, 中国医师协会呼吸医师分会间质性肺疾病工作委员会. 中国肺结节病诊断和治疗专家共识[J]. 中华结核和呼吸杂志,2019,42(9): 685-693.
10 JIANG L, HE J, SHI X, et al. Prognosis of synchronous and metachronous multiple primary lung cancers: Systematic review and meta-analysis[J]. Lung Cancer Amst Neth, 2015, 87(3): 303?310. doi:10.1016/j.lungcan.2014.12.013
11 郭海法,毛锋,张辉,等.同时性多原发肺癌的预后及生存相关因素研究[J].中国肺癌杂志,2017,20(1):21-27.
12 丁小胜,汤传昊,王志杰,等.雌激素在非小细胞肺癌中的研究进展[J].中国肺癌杂志,2017,20(7):499-504.
13 LIU W, KONDURI S D, BANSAL S, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function[J]. Biol Chem, 2006, 281(15): 9837?9840. doi:10.1074/jbc.c600001200
14 HYDER S M, NAWAZ Z, CHIAPPETTA C, et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor[J]. Cancer Res, 2000, 60(12): 3183?3190.
15 IKEDA K, SHIRAISHI K, YOSHIDA A, et al. Synchronous Multiple Lung Adenocarcinomas: Estrogen Concentration in Peripheral Lung[J]. PloS One, 2016, 11(8): e0160910. doi:10.1371/journal.pone.0160910
16 HOFFMAN R M, ATALLAH R P, STRUBLE R D, et al. Lung Cancer Screening with Low-Dose CT: A Meta-Analysis[J]. Gen Intern Med, 2020, 35(10): 3015?3025. doi:10.1007/s11606-020-05951-7
17 YATABE Y, BORCZUK A C, POWELL C A. Do all lung adenocarcinomas follow a stepwise progression?[J]. Lung Cancer Amst Neth, 2011, 74(1): 7?11. doi:10.1016/j.lungcan.2011.05.021
18 ICHINOSE J, KAWAGUCHI Y, NAKAO M, et al. Utility of Maximum CT Value in Predicting the Invasiveness of Pure Ground-Glass Nodules[J]. Clin Lung Cancer, 2020, 21(3): 281?287. doi:10.1016/j.cllc.2020.01.015
19 MARTIN B, PAESMANS M, MASCAUX C, et al. Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis[J]. Br J Cancer, 2004, 91(12): 2018?2025. doi:10.1038/sj.bjc.6602233
20 JI Y, ZHENG M, YE S, et al. PTEN and Ki67 expression is associated with clinicopathologic features of non-small cell lung cancer[J]. Biomed Res, 2014, 28(6): 462?467. doi:10.7555/jbr.27.20130084
21 RAMI-PORTA R, ASAMURA H, TRAVIS W D, et al. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017, 67(2): 138?155. doi:10.3322/caac.21390
22 沈涛,卢珠明. 同时性多原发肺癌淋巴结转移规律的临床研究[J]. 岭南现代临床外科, 2021, 21(5): 561.
23 LIU W, YANG H S, ZHI F H, et al. Macrophage migration inhibitory factor may contribute to the occurrence of multiple primary lung adenocarcinomas[J]. Clin Transl Med, 2023, 13(10): e1368. doi:10.1002/ctm2.1368
24 SAKURAI T, OKUYAMA Y, KOBAYASHI S, et al. GITR controls intestinal inflammation by suppressing IL-15-dependent NK cell activity[J]. FASEB J Off Publ Fed Am Soc Exp Biol, 2020, 34(11): 14820?14831. doi:10.1096/fj.202001675r
25 RONCHETTI S, RICCI E, PETRILLO M G, et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein: A key marker of functional regulatory T cells[J]. Immunol Res, 2015, 2015(1): 171520. doi:10.1155/2015/171520
26 WANG Y, CHEN D, LIU Y, et al. Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung cancers[J]. Cell Death Dis, 2023, 14(7): 462. doi:10.1038/s41419-023-05992-w
27 WANG Y, HUANG Z, LI B, et al. Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer[J]. CANCER Immunol Immunother, 2024, 73(6): 111. doi:10.1007/s00262-024-03703-8
28 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2023版)[J]. 中华医学杂志, 2023, 103(27): 2037-2074.
29 WATANABE T, TANAHASHI M, SUZUKI E, et al. Surgical treatment for synchronous multiple primary lung cancer: Is it possible to achieve both curability and preservation of the pulmonary function?[J]. Thorac Cancer, 2021, 12(22): 2996?3004. doi:10.1111/1759-7714.14164
30 ISHIKAWA Y, NAKAYAMA H, ITO H, et al. Surgical treatment for synchronous primary lung adenocarcinomas[J]. Ann Thorac Surg, 2014, 98(6): 1983?1988. doi:10.1016/j.athoracsur.2014.07.006
31 彭岳, 王晖, 谢厚耐, 等. 同时性多原发肺腺癌的外科治疗及预后[J]. 中国肺癌杂志, 2017, 20(2): 107?113.
32 姜格宁, 陈昶, 朱余明, 等. 上海市肺科医院磨玻璃结节早期肺腺癌的诊疗共识(第一版)[J]. 中国肺癌杂志,2018, 21(3): 147-159.
33 中国医药教育协会肺癌医学教育委员会, 中国胸外科肺癌联盟, 中国抗癌协会肿瘤消融治疗专业委员会,等. 多发磨玻璃结节样肺癌多学科诊疗中国专家共识(2024年版)[J]. 中华内科杂志,2024,63(2): 153-169.
34 SUN C, MEZZADRA R, SCHUMACHER T N. Regulation and Function of the PD-L1 Checkpoint[J]. Immunity, 2018, 48(1): 434?452. doi:10.1016/j.immuni.2018.03.014
35 SCHOENFELD A J, RIZVI H, BANDLAMUDI C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas[J]. Ann Oncol Off J Eur Soc Med Oncol, 2020, 31(5): 599?608. doi:10.1016/j.annonc.2020.01.065
36 HU C, ZHAO L, LIU W, et al. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers[J]. Immunother Cancer, 2021, 9(12): e003773. doi:10.1136/jitc-2021-003773
37 SODA M, TAKADA S, TAKEUCHI K, et al. A mouse model for EML4-ALK-positive lung cancer[J]. Proc Natl Acad Sci U S A, 2008, 105(50): 19893?19897. doi:10.1073/pnas.0805381105
38 PAN Y, ZHANG Y, LI Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features[J]. Lung Cancer Amst Neth, 2014, 84(2): 121?126. doi:10.1016/j.lungcan.2014.02.007
39 FAN L, FENG Y, WAN H, et al. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: A systematic review and meta-analysis[J]. PloS One, 2014, 9(6); e100866. doi:10.1371/journal.pone.0100866
40 CHIA P L, MITCHELL P, DOBROVIC A, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors[J]. Clin Epidemiol, 2014, 6(1): 423?432.
文章导航

/